


Life Length and its technology

Life Length is a Spanish life sciences and biotechnology company with more than a decade of experience in the health field. World leader in telomere measurement through its patented and exclusive high-performance technology, known as **TAT® (Telomere Analysis Technology)**. This technology allows us to measure a multitude of variables associated with telomeres (TAVs) and relate them to the probability of developing prostate cancer.

Telomeres are regions at the ends of chromosomes that play a crucial role in the maintenance and integrity of DNA. Telomere length is closely related to cellular aging (due to shortening) and the development of certain pathologies, such as prostate cancer ⁴.



For more information, consult your urologist.

(1) Cáncer de Próstata - SEOM: Sociedad Española de Oncología Médica. (n.d.), from Casos nuevos por año son diagnosticados en España.

(2) Sung, H., et al. (2021). Global Cancer Statistics 2020: <https://doi.org/10.3322/CAAC.21660>

(3) Dimensiones del cáncer | AECC Observatorio. (n.d.), from Casos nuevos por año son diagnosticados en España.

(4) Xu, J., et al. (2020). Leukocyte telomere length is associated with aggressive prostate cancer in localized prostate cancer patients. EBioMedicine, 52. <https://doi.org/10.1016/J.EBIOM.2019.102616>

 LIFE LENGTH
LABORATORIES

www.lifelength.com



Rev. 2

Telomeric biomarker for the detection of Prostate cancer



Are you worried about your prostate health?

 LIFE LENGTH
LABORATORIES

Prostate health

The prostate is a gland the size and shape of a walnut. With age it tends to enlarge naturally. However, there are other diseases that can affect the prostate. Risk factors such as age, family history, the presence of genetic alterations or race have been related to the appearance of prostate cancer (PCa)¹.

About prostate cancer


PCa is the most **common cancer in men in Spain and the second in the world**^{1,2}:

Each year:

+ 35.000 Men are diagnosed with PCa in Spain³.

6.000 Deaths due to the disease in Spain³.

90% of cases are diagnosed in men over 65 years of age. Furthermore, it is estimated that the disease will affect **1 in 8 men** throughout their lives¹.



Biomarker for prostate cancer

There is a novel non-invasive test that allows establishing a relationship between the result of **your telomere measurement and the probability of presenting PCa through a simple blood test**.

This test could be used as a clinical tool to enhance the detection of PCa in patients at risk of developing the disease.

Advantages of the test

- ✓ Clinically proven
- ✓ Avoid unnecessary biopsies
- ✓ **Non invasive**, only requires a blood sample
- ✓ Additional tool for PCa detection

Am I a candidate for the test?

The test is indicated for men over 40 years of age who have a PSA between **3 and 10 ng/ml** and who are suspected of having prostate cancer.

How is the test performed?

The test is performed through a **simple blood draw**. This sample is sent to a central laboratory for the analysis of its telomere profile, which, along with certain clinical variables, allows for the determination of the likelihood of having significant prostate cancer (requiring treatment or intervention) through a risk score.

How long does it take to receive my results?

The test results will be available to share with you by your urologist between 7 to 10 days after receiving the sample at the laboratory.



Early detection of prostate cancer is essential for successful treatment and long-term survival.